Part 4: Early Mobility and Exercise & Sleep Promotion
Safety screening criteria for ICU mobilization, progressive mobility levels, ICU-acquired weakness diagnosis and prevention, barriers to early mobility, sleep disruption assessment and causes, non-pharmacologic and pharmacologic sleep interventions, and circadian rhythm management.
Early Mobility and Exercise in the ICU
Rationale
Prolonged immobility in the ICU leads to rapid and profound skeletal muscle wasting (up to 2–4% loss of muscle cross-sectional area per day), ICU-acquired weakness (ICUAW), functional decline, prolonged ventilator dependence, and worse long-term outcomes. Early mobility — defined as rehabilitation and mobilization initiated within 24–72 hours of ICU admission — is a core element of the ABCDEF bundle and is supported by strong evidence.1 2 3
Key Recommendations
| # | Recommendation | Strength |
|---|---|---|
| 1 | Early mobility and exercise should be performed in critically ill adults to reduce delirium incidence and duration, improve functional outcomes, and increase ventilator-free days | Strong recommendation |
| 2 | Rehabilitation should begin within 24–48 hours of ICU admission in patients who are hemodynamically stable | Conditional recommendation |
| 3 | Physical and occupational therapy should be integrated into daily ICU care | Conditional recommendation |
| 4 | A mobility protocol with defined safety criteria and progressive levels should be implemented | Conditional recommendation |
Evidence for Early Mobility
| Outcome | Benefit | Key Trials |
|---|---|---|
| Duration of mechanical ventilation | Reduced by 1.5–2.5 days | Schweickert et al. 20092 |
| ICU length of stay | Reduced by 1.5–3.0 days | Schweickert et al. 20092 |
| Hospital length of stay | Reduced by 2.0–4.0 days | Multiple trials |
| Delirium duration | Reduced by 2.0 days | Schweickert et al. 20092 |
| Functional independence at discharge | Improved (Barthel index higher) | Schweickert et al. 20092; Morris et al. 20083 |
| ICUAW incidence | Reduced | Observational data |
| Return to independent function | Higher rates | Observational data |
| Mortality | No consistent reduction in short-term mortality; trend toward improvement | Mixed evidence |
| Safety | Adverse event rate < 1–4% of sessions (desaturation, hypotension most common; serious events rare) | Multiple safety analyses4 |
Safety Screening for Mobilization
Before each mobilization session, a standardized safety screen should be completed. Mobilization should NOT be initiated or should be PAUSED if any of the following “red light” criteria are present. “Yellow light” criteria require careful risk-benefit assessment and modification of the mobility plan.1 4
Red Light Criteria (Do NOT Mobilize — Contraindicated)
| System | Criterion |
|---|---|
| Cardiovascular | Mean arterial pressure < 55 mmHg or > 140 mmHg |
| Heart rate < 40 or > 150 bpm | |
| New-onset arrhythmia requiring active treatment | |
| Active myocardial ischemia (new ST changes, troponin rising, chest pain) | |
| New or escalating vasopressor requirement within the past 2 hours | |
| Active hemorrhage with hemodynamic instability | |
| Respiratory | FiO2 > 0.80 |
| PEEP > 15 cmH2O | |
| SpO2 < 88% at rest | |
| Active ventilator asynchrony not resolved | |
| Unsecured airway | |
| Neurologic | Active seizures |
| Uncontrolled intracranial hypertension (ICP > 20 mmHg) | |
| Acute spinal cord injury — not cleared for mobilization | |
| Declining neurologic status (GCS drop ≥ 2 points) | |
| Other | Active procedure/transport planned within 30 minutes |
| Patient refusal (if able to communicate) | |
| Unstable fractures not stabilized | |
| Femoral arterial sheath in place |
Yellow Light Criteria (Proceed with Caution — Modify Plan)
| System | Criterion | Modification |
|---|---|---|
| Cardiovascular | MAP 55–65 on stable low-dose vasopressor (norepinephrine ≤ 0.1 mcg/kg/min) | In-bed exercises, passive ROM; consider seated position |
| Stable atrial fibrillation with controlled rate | Monitor; reduce activity level if rate > 130 | |
| Respiratory | FiO2 0.60–0.80 | In-bed exercises; may sit at edge of bed with continuous SpO2 monitoring |
| PEEP 10–15 | In-bed to seated; avoid standing if SpO2 drops > 4% | |
| High-flow nasal cannula or non-invasive ventilation | May mobilize with portable device; ensure equipment availability | |
| Sedation | RASS −2 to −3 | Passive/active-assisted ROM; seated position may be attempted |
| Lines/devices | Femoral venous catheter, chest tube, epidural | Mobilize with attention to line security; may limit standing/ambulation with femoral lines |
| CRRT running | May mobilize with institutional protocol; ensure machine on mobile cart; coordinate with nursing | |
| ECMO (femoral cannulation) | In-bed exercises; some centers mobilize ECMO patients to standing/ambulation with experienced team | |
| Other | Obesity (BMI > 40) | Extra staff for safety; appropriate equipment (bariatric bed, standing device); lower mobility level initially |
| Orthopedic precautions (weight-bearing restrictions) | Adapt activity within weight-bearing limits |
Stopping Criteria During Mobilization
| Parameter | Stop and Return to Prior Level If: |
|---|---|
| SpO2 | Drops below 88% (or > 4% from baseline) and does not recover with rest |
| Heart rate | Increases to > 70% age-predicted max (or > 40 bpm above resting) or drops below 50 bpm |
| Blood pressure | SBP > 200 or < 80 mmHg; MAP < 55 mmHg |
| Respiratory rate | > 40 breaths/min |
| Ventilator | New asynchrony, distress, desaturation |
| Neurologic | New confusion, agitation (RASS > +2), loss of consciousness |
| Patient | Reports significant pain (NRS > 7), extreme fatigue, lightheadedness, or requests to stop |
| Device | Line displacement, tube dislodgement, or equipment malfunction |
Mobility Progression Levels
A structured, progressive mobility protocol with defined levels helps standardize care and allows safe advancement based on patient response.1 3 4
| Level | Activity | Patient Criteria | Staff Required | Equipment |
|---|---|---|---|---|
| Level 0 | No mobilization | Fails red-light safety screen | — | — |
| Level 1: Passive Range of Motion | Passive ROM all extremities (10 reps each major joint, 2× daily); turning and positioning q 2 h | RASS −5 to −3; hemodynamically unstable; receiving NMBA; immediately post-operative | 1 (RN or PT/OT) | None specific |
| Level 2: Active-Assisted / Active ROM in Bed | Active-assisted or active ROM exercises; bed cycling (supine cycle ergometer); in-bed functional electrical stimulation; head-of-bed elevation ≥ 30° | RASS −2 to +1; following simple commands (inconsistently acceptable); able to assist with movement | 1–2 (PT/OT ± RN) | Cycle ergometer; resistance bands |
| Level 3: Seated Upright / Edge of Bed (Dangling) | Sitting upright in bed (HOB ≥ 60°); sitting at edge of bed with feet dangling; active upper and lower extremity exercises in seated position | RASS −1 to +1; following commands; some trunk control; hemodynamically stable (or on stable low-dose vasopressor) | 2 (PT + RN minimum) | Non-slip footwear; gait belt |
| Level 4: Standing and Transfers | Standing at bedside (assisted or with standing frame); transfer to chair (pivot or slide board); sitting in chair (goal ≥ 20 min, progress to 2–4 h); active exercises in chair | RASS 0 to +1; able to bear weight (partial or full); following commands consistently; adequate trunk control | 2–3 (PT + RN ± aide) | Standing frame or tilt table; chair; gait belt; walker |
| Level 5: Ambulation | Walking in room or hallway (assisted); progressive distance (goal: increase daily); stair climbing if indicated for discharge planning | RASS 0 to +1; able to weight-bear fully; following commands; adequate endurance for > 1 min standing | 2–3 (PT + RN ± aide) | Walker or rolling walker; portable SpO2 monitor; IV pole; portable ventilator if applicable |
Mobility in Special Populations
| Population | Considerations |
|---|---|
| Mechanically ventilated | May mobilize to all levels with adequate ventilator settings and staffing; ensure ETT/tracheostomy is secure; may need portable ventilator for ambulation; coordinate with RT |
| Tracheostomy | Often facilitates earlier and more aggressive mobilization; ensure speaking valve or capping trial before stair climbing |
| ECMO (femoral) | Institutional variability; many centers now mobilize to Level 3–5 with experienced team; femoral cannula must be secure; anticoagulation managed |
| CRRT | In-bed to chair mobilization generally feasible; some centers ambulate with portable CRRT; coordinate with nursing |
| Open abdomen | Limit to Level 1–2; risk of evisceration with upright posture; follow surgical team guidance |
| Post-cardiac surgery | Sternal precautions (limit upper extremity activity for 6–8 weeks); otherwise aggressive mobility; often ambulating by POD 1 |
| Neurologic injury (stroke, TBI) | Early mobilization is recommended but timing depends on condition; may need modified techniques; PT/OT specialization |
| Morbid obesity | Appropriate equipment (bariatric beds, ceiling lifts, larger walkers); extra staff; start at lower levels |
Interprofessional Mobility Team
| Team Member | Role |
|---|---|
| Physical Therapist (PT) | Assess functional status; design mobility plan; lead mobilization sessions; progress activity levels |
| Occupational Therapist (OT) | Assess ADL capacity; upper extremity function; cognitive engagement during activities; adaptive equipment |
| Bedside Nurse (RN) | Safety screening; pain assessment before/during mobility; monitor vitals; secure lines and devices; co-lead sessions |
| Respiratory Therapist (RT) | Manage ventilator during mobility; accompany mechanically ventilated patients; oxygen support |
| Nursing Aide / Patient Care Tech | Assist with transfers; equipment management; safety |
| Physician / APP | Order mobility; set sedation targets to facilitate mobility; address safety concerns; coordinate SAT timing with mobility sessions |
| Pharmacist | Optimize sedation and pain management to facilitate mobility; identify medications causing excessive sedation |
ICU-Acquired Weakness (ICUAW)
Definition
ICU-acquired weakness is a clinically detectable, diffuse, symmetric weakness developing after the onset of critical illness with no identifiable etiology other than the critical illness itself. It encompasses critical illness polyneuropathy (CIP), critical illness myopathy (CIM), and critical illness neuromyopathy (CINM — combined).5 6
Incidence
| Population | ICUAW Incidence |
|---|---|
| All ICU admissions > 48 hours | 25–33% |
| Mechanical ventilation > 7 days | 50–67% |
| Sepsis / systemic inflammatory response | 50–70% |
| Multi-organ failure | 60–100% |
Risk Factors for ICUAW
| Risk Factor | Mechanism / Evidence |
|---|---|
| Sepsis and systemic inflammation | Cytokine-mediated muscle catabolism; microvascular injury to nerves |
| Multi-organ dysfunction | Compound metabolic insult to neuromuscular system |
| Prolonged mechanical ventilation | Diaphragm atrophy (ventilator-induced diaphragmatic dysfunction — VIDD); immobility |
| Immobility / bed rest | 1.5–2% loss of muscle strength per day of bed rest; up to 4% loss of muscle cross-sectional area per day |
| Hyperglycemia | Prospective data suggest intensive insulin therapy reduces ICUAW incidence |
| Corticosteroids | Dose and duration dependent; particularly when combined with NMBAs (acute myopathy of intensive care) |
| Neuromuscular blocking agents | Especially when used > 48 hours or combined with corticosteroids |
| Aminoglycosides | Neuromuscular junction effects |
| Malnutrition / inadequate protein | Accelerates muscle catabolism |
| Duration of ICU stay | Cumulative exposure to all risk factors |
| Advanced age | Lower physiologic reserve; sarcopenia at baseline |
Subtypes of ICUAW
| Feature | Critical Illness Polyneuropathy (CIP) | Critical Illness Myopathy (CIM) | Critical Illness Neuromyopathy (CINM) |
|---|---|---|---|
| Primary pathology | Axonal degeneration of motor and sensory nerves | Myosin loss; muscle necrosis; atrophy | Combined nerve and muscle involvement |
| Weakness pattern | Distal > proximal | Proximal > distal (or diffuse) | Mixed |
| Sensory involvement | Yes (reduced sensation distally) | No | Variable |
| Deep tendon reflexes | Decreased or absent | Normal or decreased | Variable |
| EMG/NCS findings | Reduced amplitude of motor and sensory nerve potentials; normal conduction velocity | Reduced amplitude of motor potentials; normal sensory potentials; short-duration, low-amplitude motor unit potentials | Combined features |
| Muscle biopsy | Normal or denervation atrophy | Type II fiber atrophy; thick filament (myosin) loss; necrosis | Combined |
| Recovery | Slow (months to years); may be incomplete | Often faster; usually more complete | Variable |
Diagnosis of ICUAW
Medical Research Council (MRC) Sum Score
The MRC Sum Score is the clinical standard for diagnosing ICUAW. It requires the patient to be alert and cooperative (RASS 0 to +1, able to follow commands).5
Six muscle groups are tested bilaterally (12 total), each graded 0–5:
| Muscle Group | Movement Tested |
|---|---|
| Shoulder abduction | Raise arms away from body |
| Elbow flexion | Bend elbows |
| Wrist extension | Extend wrists upward |
| Hip flexion | Lift legs off bed |
| Knee extension | Straighten knees |
| Ankle dorsiflexion | Pull feet toward head |
MRC Grading Scale (per muscle group):
| Grade | Description |
|---|---|
| 0 | No visible contraction |
| 1 | Visible contraction without limb movement |
| 2 | Active movement with gravity eliminated |
| 3 | Active movement against gravity |
| 4 | Active movement against gravity and resistance |
| 5 | Normal strength |
MRC Sum Score Interpretation:
| Score | Interpretation |
|---|---|
| 60 | Normal (maximum score) |
| 48–59 | Mild weakness |
| 36–47 | Moderate weakness |
| < 48 | ICUAW diagnostic threshold |
| < 36 | Severe ICUAW |
Limitation: Requires patient cooperation; cannot be performed in comatose, deeply sedated, or delirious patients.
Additional Diagnostic Modalities
| Test | When to Consider | What It Shows |
|---|---|---|
| Electromyography (EMG) / Nerve Conduction Studies (NCS) | When clinical assessment is equivocal; to differentiate CIP from CIM; when weakness is asymmetric (concern for alternative diagnosis) | CIP: low compound muscle action potential (CMAP) and sensory nerve action potential (SNAP) amplitudes with preserved conduction velocity; CIM: low CMAP with preserved SNAP, myopathic motor unit potentials |
| Ultrasound (muscle) | Bedside screening; trending muscle mass over time | Decreased muscle layer thickness (quadriceps, biceps); can detect loss of echogenicity (edema, necrosis) |
| Muscle biopsy | Rarely needed; research; equivocal EMG/NCS | Confirms CIM (myosin loss, type II fiber atrophy) vs. CIP (denervation atrophy) |
| Diaphragm ultrasound | Suspected ventilator-induced diaphragmatic dysfunction | Diaphragm thickness and thickening fraction during spontaneous breathing; thickness < 0.2 cm or thickening fraction < 20% suggests dysfunction |
Prevention and Management of ICUAW
| Strategy | Evidence Level | Details |
|---|---|---|
| Early mobilization | Strong | Begin within 24–48 hours; progressive protocol as described above; the single most impactful intervention |
| Minimize sedation | Strong | Light sedation targets; daily SAT; analgesia-first approach |
| Glycemic control | Moderate | Target glucose 140–180 mg/dL (avoid both hyperglycemia and hypoglycemia) |
| Minimize corticosteroids | Moderate | Use lowest effective dose for shortest duration |
| Minimize neuromuscular blockers | Moderate | Limit NMBA use to specific indications (see Part 2); shortest duration possible |
| Adequate nutrition | Moderate | Early enteral nutrition; protein goal 1.2–2.0 g/kg/day; avoid overfeeding |
| Avoid aminoglycosides | Low | Use alternative antibiotics when possible |
| In-bed cycling | Moderate | Supine cycle ergometry; improves functional outcomes even in deeply sedated patients |
| Functional electrical stimulation (FES) | Low-Moderate | Neuromuscular electrical stimulation of large muscle groups; may preserve muscle mass |
| Diaphragm protective ventilation | Emerging | Spontaneous breathing efforts preserved at appropriate level; avoid both over-assistance and excessive effort |
Sleep Disruption in the ICU
Prevalence and Consequences
Sleep disruption is nearly universal in ICU patients, with most experiencing severe fragmentation, reduced total sleep time, altered sleep architecture, and disrupted circadian rhythms.1 7
| Parameter | Normal Sleep | Typical ICU Sleep |
|---|---|---|
| Total sleep time | 7–9 hours | 2–5 hours (fragmented) |
| Sleep efficiency | > 85% | 20–60% |
| REM sleep (% of total) | 20–25% | 0–6% (markedly reduced or absent) |
| Slow-wave (N3) sleep | 15–20% | Severely reduced or absent |
| Number of awakenings | 0–5/night | 20–60+/night |
| Circadian rhythm | Intact | Absent or severely disrupted |
Consequences of ICU Sleep Disruption
| Consequence | Mechanism |
|---|---|
| Delirium | Sleep deprivation is an independent risk factor for ICU delirium |
| Immune dysfunction | Reduced natural killer cell activity; impaired cytokine regulation; increased infection susceptibility |
| Impaired wound healing | Growth hormone is primarily secreted during slow-wave sleep |
| Respiratory muscle weakness | Fatigued diaphragm; impaired ventilator weaning |
| Hemodynamic instability | Sympathetic activation; increased heart rate and blood pressure variability |
| Insulin resistance | Glucose dysregulation; hyperglycemia |
| Psychological distress | Anxiety, depression, hallucinations; contributes to post-ICU PTSD |
| Cognitive impairment | Impaired memory consolidation; reduced attention |
| Patient suffering | Rated by survivors as one of the most distressing ICU experiences |
Causes of Sleep Disruption in the ICU
| Category | Specific Causes |
|---|---|
| Environmental | Noise (alarms, monitors, ventilators, conversations, overhead pages — often > 70 dB; threshold for arousal ~40–50 dB); light (24-hour bright lighting; lack of day-night differentiation); temperature (too warm or too cold) |
| Care activities | Vital sign checks, medication administration, labs, dressing changes, suctioning, turning — often concentrated at night; studies show 40–60 patient interactions per night |
| Medications | Vasopressors (catecholamines increase arousal); corticosteroids (alter circadian rhythm, increase arousal); benzodiazepines (alter sleep architecture — suppress REM and slow-wave sleep despite being sedating); propofol (alters sleep architecture); opioids (suppress REM); beta-blockers (suppress melatonin secretion); fluoroquinolones |
| Mechanical ventilation | Patient-ventilator asynchrony; ventilator mode (assist/control may be less sleep-friendly than pressure support); alarms; discomfort from endotracheal tube |
| Illness factors | Pain; dyspnea; anxiety; delirium; sepsis and inflammation (cytokines disrupt circadian clock genes); metabolic derangements; sleep-disordered breathing |
| Psychological | Anxiety; fear; unfamiliar environment; loss of autonomy; isolation from family |
Assessment of Sleep in the ICU
| Tool | Description | Limitations |
|---|---|---|
| Polysomnography (PSG) | Gold standard; measures EEG, EOG, EMG | Impractical for routine ICU use; expensive; requires technician; ICU sleep architecture often uninterpretable by standard criteria |
| Richards-Campbell Sleep Questionnaire (RCSQ) | Patient-reported 5-item visual analog scale (sleep depth, falling asleep, awakenings, returning to sleep, sleep quality); score 0–100 (higher = better) | Requires patient ability to self-report; subjective; may not reflect actual sleep physiology |
| Actigraphy | Wrist-worn accelerometer; distinguishes sleep from wake based on movement | Overestimates sleep in immobile patients; cannot determine sleep stage |
| Nurse assessment | Bedside nurse observes and documents sleep/wake | Poor correlation with PSG; nurses overestimate patient sleep time |
| Bispectral Index (BIS) | Processed EEG; some correlation with sleep stages | Not validated for sleep assessment; confounded by sedation |
Recommendation: The RCSQ is the most practical validated tool for routine clinical assessment of ICU sleep quality. Use it at least daily for patients able to self-report.1
Non-Pharmacologic Sleep Promotion Protocol
Non-pharmacologic interventions are first-line for sleep promotion in the ICU (strong recommendation).1 7 8
Comprehensive Sleep Promotion Bundle
| Domain | Intervention | Implementation Details |
|---|---|---|
| Noise reduction | Minimize alarm volumes to lowest effective setting | Adjust monitor alarms per institutional protocol; disable non-critical alarms overnight |
| Close patient room doors at night | 22:00–06:00 | |
| Use earplugs | Offer to all patients nightly; disposable foam earplugs; ensure patient can still hear emergency communication | |
| Minimize staff conversation near patient rooms at night | Staff education; designate quiet zones | |
| Turn off or mute TV at 22:00 | Unless patient requests otherwise | |
| Minimize overhead pages at night | Transition to individual pagers/phones between 22:00–06:00 | |
| Target ambient noise < 45 dB at night | Use decibel monitoring when available | |
| Light management | Dim lights at night (22:00–06:00) | Reduce to lowest safe level; use task lighting for necessary care; avoid overhead fluorescent lights |
| Provide eye masks | Offer nightly; ensure comfort; replace as needed | |
| Maximize daytime light exposure | Open blinds 06:00–20:00; consider bright light therapy (≥ 2,500 lux) in rooms without windows | |
| Maintain consistent light-dark cycle | Same schedule daily to entrain circadian rhythm | |
| Care clustering | Cluster care activities to minimize nighttime interruptions | Coordinate medication administration, vital signs, lab draws, and nursing assessments to occur at the same time (e.g., q 4 h rather than scattered); avoid waking for non-urgent tasks |
| Defer non-urgent labs and imaging to daytime | No routine 02:00 lab draws unless clinically indicated | |
| Minimize unnecessary vitals checks at night | Consider q 4 h vs. q 2 h vitals for stable patients overnight | |
| Environment | Optimize room temperature | Patient preference; typically 20–22°C (68–72°F) |
| Provide comfortable bedding | Extra blankets; pillow positioning | |
| Reduce unnecessary equipment noise | Turn off pumps not in use; silence idle monitors | |
| Behavioral | Establish and communicate a sleep-wake schedule | Post schedule at bedside; communicate to all care team members |
| Limit caffeine after 15:00 | For patients receiving enteral nutrition with caffeinated products | |
| Encourage daytime activity and wakefulness | Upright positioning; mobility sessions during the day; avoid excessive daytime napping | |
| Relaxation techniques | Music therapy; guided imagery; calming sounds or white noise (for patients who prefer it) | |
| Family education | Explain sleep promotion plan; family can assist with reorientation and calming |
Night-Shift Checklist (22:00–06:00)
| Time | Action |
|---|---|
| 22:00 | Dim lights; close door; offer earplugs and eye mask; silence non-critical alarms; final care cluster (meds, assessment); set quiet environment |
| 22:00–06:00 | Minimize room entry; cluster essential care at 02:00 and 05:00 if needed; perform assessments at bedside without turning on overhead lights (use penlight); defer non-urgent nursing tasks to morning |
| 06:00 | Open blinds; restore normal lighting; resume routine care schedule; assess sleep quality (RCSQ if patient can report) |
Pharmacologic Sleep Considerations
Pharmacologic agents for sleep in the ICU are second-line and should be used only when non-pharmacologic measures are insufficient. The 2018 guidelines make no strong recommendations for specific pharmacologic sleep agents due to limited ICU-specific evidence.1
Melatonin and Ramelteon
| Parameter | Melatonin | Ramelteon |
|---|---|---|
| Mechanism | Endogenous hormone that regulates circadian rhythm; acts on MT1 and MT2 receptors in suprachiasmatic nucleus | Selective MT1/MT2 receptor agonist (synthetic) |
| Dose | 1–5 mg PO/NG at 21:00 (some protocols use 0.5 mg for circadian effect, higher doses for hypnotic effect) | 8 mg PO/NG at 21:00 (single dose available) |
| Evidence in ICU | Mixed; some RCTs show reduced delirium incidence (suggestive but not definitive); may improve sleep quality; generally well-tolerated | Limited ICU data; one RCT showed reduced delirium in elderly medical patients; more consistent absorption than melatonin |
| Advantages | Low cost; minimal side effects; no respiratory depression; no dependence; may support circadian rhythm restoration | More consistent pharmacokinetics than melatonin; no respiratory depression |
| Disadvantages | Variable absorption (especially in ICU patients with impaired GI function); inconsistent product quality in supplement formulations; limited strong evidence | Requires enteral access; limited ICU evidence; more expensive than melatonin |
| Recommendation | Reasonable to trial for sleep promotion and circadian rhythm support in ICU patients (conditional, low-quality evidence) | Alternative to melatonin; same conditional recommendation |
Agents to AVOID for ICU Sleep
| Agent | Why to Avoid |
|---|---|
| Benzodiazepines (temazepam, lorazepam, midazolam) | Alter sleep architecture (suppress REM and slow-wave sleep); increase delirium risk; next-day hangover; dependence |
| Zolpidem / zaleplon | Delirium risk; residual sedation; limited ICU data; may cause complex sleep behaviors |
| Diphenhydramine | Strong anticholinergic — increases delirium risk; alters sleep architecture; residual sedation |
| Hydroxyzine | Anticholinergic; sedation; delirium risk |
| Quetiapine (as primary sleep aid without delirium) | Not indicated as a hypnotic in patients without delirium; metabolic side effects; QTc risk; may be considered at low dose (25–50 mg) for sleep in patients with active delirium who also have insomnia |
Dexmedetomidine for Nocturnal Sedation
Low-dose dexmedetomidine infusion (0.2–0.7 mcg/kg/h) at night may produce a sleep-like sedation that preserves some features of natural sleep architecture (more arousable, better preserved slow-wave features than propofol or benzodiazepines). It may be considered for:9
- Non-intubated ICU patients with severe sleep disruption refractory to non-pharmacologic measures
- Mechanically ventilated patients whose primary sedation challenge is overnight agitation/insomnia
- Patients with delirium who need nocturnal sedation support
Caution: Hemodynamic monitoring required; not a substitute for treating underlying causes of sleep disruption.
Circadian Rhythm Management in the ICU
Circadian Disruption in Critical Illness
Critical illness disrupts circadian rhythm through multiple mechanisms:7
- Constant ambient light in the ICU
- Loss of social and meal-time cues (zeitgebers)
- Medications that suppress melatonin (beta-blockers, NSAIDs) or disrupt circadian gene expression (corticosteroids)
- Inflammatory cytokines directly disrupt core clock gene function
- Sedation eliminates normal behavioral entrainment
Strategies for Circadian Rhythm Support
| Strategy | Implementation |
|---|---|
| Light-dark cycling | Bright light (> 2,500 lux) during daytime; minimal light at night; consistent timing daily |
| Meal timing | When enteral nutrition is possible, consider daytime feeding with overnight fast (or at least reduced overnight feeding rate) to support peripheral clock gene entrainment |
| Activity timing | Mobility sessions, PT/OT, and cognitive stimulation during daytime; minimize activity at night |
| Medication timing | Administer stimulating medications (corticosteroids, vasopressors when possible) during daytime; give melatonin or ramelteon at consistent nighttime hour |
| Social cues | Family visits during daytime; reorientation to date and time; TV/radio schedules consistent with day/night |
Barriers to Early Mobility and Sleep Promotion — and Solutions
Common Barriers and Implementation Strategies
| Barrier | Strategies to Overcome |
|---|---|
| Sedation depth | Implement light sedation targets; coordinate SAT timing with mobility sessions (ideally 08:00–10:00); analgesia-first approach |
| Staffing | Designate mobility team; cross-train ICU staff; use mobility aides; stagger mobilization sessions across patients |
| Safety concerns | Standardized safety screening checklist; demonstrated safety data (< 4% adverse event rate); start at lower mobility levels |
| Lines and devices | Secure all lines before mobilization; designate line-watchers during sessions; use portable equipment |
| Provider culture | Education on evidence; champion model (physician and nurse champions on each unit); regular feedback on compliance and outcomes |
| Time constraints | Embed mobility into daily routine (not add-on); coordinate with SAT, SBT, and PT schedules; set daily mobility goals at multidisciplinary rounds |
| Patient factors | Pain management before mobility; motivation and goal-setting with patient; family engagement |
| Nighttime noise and disruptions | Noise monitoring; quiet time enforcement; staff accountability; environmental modifications (door closers, alarm management) |
| Alarm fatigue | Customize alarm limits per patient; disable non-critical alarms overnight; transition to vibrating or visual alerts for non-urgent parameters |
References
Devlin JW, Skrobik Y, Gélinas C, et al. “Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU.” Crit Care Med. 2018;46(9):e825-e873. DOI: 10.1097/CCM.0000000000003299 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Schweickert WD, Pohlman MC, Pohlman AS, et al. “Early Physical and Occupational Therapy in Mechanically Ventilated, Critically Ill Patients: A Randomised Controlled Trial.” Lancet. 2009;373(9678):1874-1882. DOI: 10.1016/S0140-6736(09)60658-9 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Morris PE, Goad A, Thompson C, et al. “Early Intensive Care Unit Mobility Therapy in the Treatment of Acute Respiratory Failure.” Crit Care Med. 2008;36(8):2238-2243. DOI: 10.1097/CCM.0b013e318180b90e ↩︎ ↩︎ ↩︎
Hodgson CL, Stiller K, Needham DM, et al. “Expert Consensus and Recommendations on Safety Criteria for Active Mobilization of Mechanically Ventilated Critically Ill Adults.” Crit Care. 2014;18(6):658. DOI: 10.1186/s13054-014-0658-y ↩︎ ↩︎ ↩︎
Stevens RD, Marshall SA, Cornblath DR, et al. “A Framework for Diagnosing and Classifying Intensive Care Unit-Acquired Weakness.” Crit Care Med. 2009;37(10 Suppl):S299-S308. DOI: 10.1097/CCM.0b013e3181b6ef67 ↩︎ ↩︎
Hermans G, Van den Berghe G. “Clinical Review: Intensive Care Unit Acquired Weakness.” Crit Care. 2015;19:274. DOI: 10.1186/s13054-015-0993-7 ↩︎
Pisani MA, Friese RS, Gehlbach BK, Schwab RJ, Weinhouse GL, Jones SF. “Sleep in the Intensive Care Unit.” Am J Respir Crit Care Med. 2015;191(7):731-738. DOI: 10.1164/rccm.201411-2099CI ↩︎ ↩︎ ↩︎
Kamdar BB, Needham DM, Collop NA. “Sleep Deprivation in Critical Illness: Its Role in Physical and Psychological Recovery.” J Intensive Care Med. 2012;27(2):97-111. DOI: 10.1177/0885066610394322 ↩︎
Alexopoulou C, Kondili E, Diamantaki E, et al. “Effects of Dexmedetomidine on Sleep Quality in Critically Ill Patients: A Pilot Study.” Anesthesiology. 2014;121(4):801-807. DOI: 10.1097/ALN.0000000000000361 ↩︎